Vimian Group AB Company Description
Vimian Group AB (publ) engages in the animal health business worldwide.
It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name.
Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.
| Country | Sweden |
| Founded | 2020 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,200 |
| CEO | Carl-Johan Boudrie |
Contact Details
Address: Riddargatan 19 Stockholm, 11457 Sweden | |
| Website | vimian.com |
Stock Details
| Ticker Symbol | VIMGF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | SE0015961982 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Alireza Tajbakhsh | Head and Chief Executive Officer of VetFamily |
| Guy C. Sporri | Chief Executive Officer of Movora |
| Stefano Santarelli | Chief Executive Officer of Indical Bioscience |
| Magnus Kjellberg | Chief Executive Officer of Nextmune |
| Carl-Johan Zetterberg Boudrie | Chief Financial Officer and Interim Chief Executive Officer |
| Maria Dahllof Tullberg | Head of IR, Communications and Sustainability |
| Carl-Johan Ehn | General Counsel |
| Bart Bremer | Chief People Officer |
| Martin Bengtson | Head of M&A |